PCM
KRTX

Patient Capital Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Patient Capital Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,631
Closed -$3.68M – 45
2023
Q4 		$3.68M Sell
11,631
-164,621
-93% -$32M 0.2% 36
2023
Q3 		$29.8M Sell
176,252
-574
-0.3% -$108K 1.75% 27
2023
Q2 		$38.3M Buy
176,826
+153,451
+656% +$32.9M 2.13% 26
2023
Q1 		$4.25M Buy
23,375
+5,675
+32% +$1.09M 1.89% 29
2022
Q4 		$3.48M Hold
17,700
– – 1.69% 28
2022
Q3 		$3.98M Sell
17,700
-1,600
-8% -$324K 1.99% 25
2022
Q2 		$2.44M Buy
19,300
+1,500
+8% +$172K 1.08% 33
2022
Q1 		$2.26M Sell
17,800
-1,400
-7% -$158K 0.76% 39
2021
Q4 		$2.52M Buy
+19,200
New +$2.48M 0.72% 40

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Patient Capital Management's KRTX Position: Q1 2024 in Review

Patient Capital Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 11,631 shares — an estimated $3.68M sold.

Patient Capital Management first reported a position in KRTX in Q4 2021 and held it in 9 quarters. The position peaked at $38.3M in Q2 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Patient Capital Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Patient Capital Management sold 11,631 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.68M.
  • Patient Capital Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
  • Patient Capital Management's Karuna Therapeutics, Inc. Common Stock position peaked at $38.3M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Patient Capital Management's 13F filing for Q1 2024, filed 15 May 2024.